Annual SG&A
$24.56 M
+$9.24 M+60.32%
30 June 2024
Summary:
Renovaro Biosciences annual selling, general & administrative expenses is currently $24.56 million, with the most recent change of +$9.24 million (+60.32%) on 30 June 2024. During the last 3 years, it has risen by +$17.00 million (+224.92%). RENB annual SG&A is now at all-time high.RENB Selling, General & Administrative Expenses Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly SG&A
$5.30 M
+$302.70 K+6.06%
30 September 2024
Summary:
Renovaro Biosciences quarterly selling, general & administrative expenses is currently $5.30 million, with the most recent change of +$302.70 thousand (+6.06%) on 30 September 2024. Over the past year, it has increased by +$1.68 million (+46.59%). RENB quarterly SG&A is now -36.05% below its all-time high of $8.29 million, reached on 30 September 2023.RENB Quarterly SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM SG&A
-$1.23 B
-$115.69 M-10.42%
30 September 2024
Summary:
Renovaro Biosciences TTM selling, general & administrative expenses is currently -$1.23 billion, with the most recent change of -$115.69 million (-10.42%) on 30 September 2024. Over the past year, it has dropped by -$1.24 billion (-6672.33%). RENB TTM SG&A is now -3574425.07% below its all-time high of $24.56 million, reached on 30 June 2024.RENB TTM SG&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RENB Selling, General & Administrative Expenses Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +60.3% | +46.6% | -6672.3% |
| 3 y3 years | +224.9% | +33.8% | -10000.0% |
| 5 y5 years | +191.7% | +137.2% | -10000.0% |
RENB Selling, General & Administrative Expenses High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +224.9% | -36.0% | +90.0% | -228.1% | at low |
| 5 y | 5 years | at high | +244.9% | -36.0% | +256.6% | -437.1% | at low |
| alltime | all time | at high | >+9999.0% | -36.0% | <-9999.0% | at low |
Renovaro Biosciences Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $5.30 M(+6.1%) | $21.57 M(-12.2%) |
| June 2024 | $24.56 M(+60.3%) | $5.00 M(-34.7%) | $24.56 M(+9.1%) |
| Mar 2024 | - | $7.65 M(+111.6%) | $22.51 M(+20.7%) |
| Dec 2023 | - | $3.62 M(-56.4%) | $18.65 M(-2.1%) |
| Sept 2023 | - | $8.29 M(+180.8%) | $19.05 M(+24.4%) |
| June 2023 | $15.32 M(+6.9%) | - | - |
| June 2023 | - | $2.95 M(-22.2%) | $15.32 M(-1.3%) |
| Mar 2023 | - | $3.80 M(-5.4%) | $15.53 M(+6.9%) |
| Dec 2022 | - | $4.01 M(-11.9%) | $14.52 M(+0.4%) |
| Sept 2022 | - | $4.56 M(+44.2%) | $14.47 M(+1.0%) |
| June 2022 | $14.33 M(+89.6%) | $3.16 M(+13.2%) | $14.33 M(+8.8%) |
| Mar 2022 | - | $2.79 M(-29.6%) | $13.18 M(+7.2%) |
| Dec 2021 | - | $3.96 M(-10.3%) | $12.29 M(+19.7%) |
| Sept 2021 | - | $4.42 M(+120.1%) | $10.27 M(+34.6%) |
| June 2021 | $7.56 M(+6.1%) | $2.01 M(+5.4%) | $7.63 M(+7.1%) |
| Mar 2021 | - | $1.90 M(-1.9%) | $7.12 M(+6.2%) |
| Dec 2020 | - | $1.94 M(+9.1%) | $6.70 M(-4.2%) |
| Sept 2020 | - | $1.78 M(+18.7%) | $7.00 M(-1.7%) |
| June 2020 | $7.12 M(-15.4%) | $1.50 M(+0.8%) | $7.12 M(-1.1%) |
| Mar 2020 | - | $1.49 M(-33.5%) | $7.20 M(-6.1%) |
| Dec 2019 | - | $2.24 M(+17.6%) | $7.66 M(-14.9%) |
| Sept 2019 | - | $1.90 M(+20.7%) | $9.01 M(+7.0%) |
| June 2019 | $8.42 M(+79.4%) | $1.57 M(-19.3%) | $8.42 M(+9.7%) |
| Mar 2019 | - | $1.95 M(-45.5%) | $7.67 M(-4.8%) |
| Dec 2018 | - | $3.58 M(+172.5%) | $8.06 M(+45.5%) |
| Sept 2018 | - | $1.31 M(+58.6%) | $5.54 M(+18.0%) |
| June 2018 | $4.69 M | $828.60 K(-64.6%) | $4.69 M(+4.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | $2.34 M(+121.3%) | $4.49 M(+80.8%) |
| Dec 2017 | - | $1.06 M(+125.8%) | $2.49 M(+26.8%) |
| Sept 2017 | - | $468.20 K(-25.6%) | $1.96 M(-15.6%) |
| June 2017 | $2.32 M(+75.1%) | $629.10 K(+89.9%) | $2.32 M(+6.9%) |
| Mar 2017 | - | $331.20 K(-37.7%) | $2.17 M(+2.7%) |
| Dec 2016 | - | $531.40 K(-36.1%) | $2.12 M(+10.0%) |
| Sept 2016 | - | $831.40 K(+73.8%) | $1.92 M(+44.9%) |
| June 2016 | $1.33 M(+28.2%) | $478.50 K(+74.6%) | $1.33 M(+56.4%) |
| Mar 2016 | - | $274.00 K(-19.1%) | $848.30 K(-31.6%) |
| Dec 2015 | - | $338.60 K(+43.7%) | $1.24 M(-29.6%) |
| Sept 2015 | - | $235.70 K(-64.6%) | $1.76 M(-26.4%) |
| June 2015 | $1.04 M(-51.0%) | - | - |
| Mar 2015 | - | $665.00 K(-22.7%) | $2.39 M(+13.1%) |
| Dec 2014 | $2.11 M(+5599.7%) | $860.60 K(+135.5%) | $2.11 M(+67.5%) |
| Sept 2014 | - | $365.50 K(-27.0%) | $1.26 M(+38.3%) |
| June 2014 | - | $500.90 K(+29.2%) | $912.60 K(+120.3%) |
| Mar 2014 | - | $387.60 K(+4685.2%) | $414.20 K(+1050.6%) |
| Dec 2013 | - | $8100.00(-49.4%) | $36.00 K(-4.0%) |
| Sept 2013 | - | $16.00 K(+540.0%) | $37.50 K(+31.6%) |
| June 2013 | - | $2500.00(-73.4%) | $28.50 K(-23.0%) |
| Mar 2013 | $37.10 K(+24.1%) | $9400.00(-2.1%) | $37.00 K(+15.6%) |
| Dec 2012 | - | $9600.00(+37.1%) | $32.00 K(-5.3%) |
| Sept 2012 | - | $7000.00(-36.4%) | $33.80 K(-17.6%) |
| June 2012 | - | $11.00 K(+150.0%) | $41.00 K(+36.7%) |
| Mar 2012 | $29.90 K(-12.8%) | $4400.00(-61.4%) | $30.00 K(+17.2%) |
| Dec 2011 | $34.30 K | $11.40 K(-19.7%) | $25.60 K(+80.3%) |
| Sept 2011 | - | $14.20 K(>+9900.0%) | $14.20 K(>+9900.0%) |
| June 2011 | - | $0.00 | $0.00 |
FAQ
- What is Renovaro Biosciences annual selling, general & administrative expenses?
- What is the all time high annual SG&A for Renovaro Biosciences?
- What is Renovaro Biosciences annual SG&A year-on-year change?
- What is Renovaro Biosciences quarterly selling, general & administrative expenses?
- What is the all time high quarterly SG&A for Renovaro Biosciences?
- What is Renovaro Biosciences quarterly SG&A year-on-year change?
- What is Renovaro Biosciences TTM selling, general & administrative expenses?
- What is the all time high TTM SG&A for Renovaro Biosciences?
- What is Renovaro Biosciences TTM SG&A year-on-year change?
What is Renovaro Biosciences annual selling, general & administrative expenses?
The current annual SG&A of RENB is $24.56 M
What is the all time high annual SG&A for Renovaro Biosciences?
Renovaro Biosciences all-time high annual selling, general & administrative expenses is $24.56 M
What is Renovaro Biosciences annual SG&A year-on-year change?
Over the past year, RENB annual selling, general & administrative expenses has changed by +$9.24 M (+60.32%)
What is Renovaro Biosciences quarterly selling, general & administrative expenses?
The current quarterly SG&A of RENB is $5.30 M
What is the all time high quarterly SG&A for Renovaro Biosciences?
Renovaro Biosciences all-time high quarterly selling, general & administrative expenses is $8.29 M
What is Renovaro Biosciences quarterly SG&A year-on-year change?
Over the past year, RENB quarterly selling, general & administrative expenses has changed by +$1.68 M (+46.59%)
What is Renovaro Biosciences TTM selling, general & administrative expenses?
The current TTM SG&A of RENB is -$1.23 B
What is the all time high TTM SG&A for Renovaro Biosciences?
Renovaro Biosciences all-time high TTM selling, general & administrative expenses is $24.56 M
What is Renovaro Biosciences TTM SG&A year-on-year change?
Over the past year, RENB TTM selling, general & administrative expenses has changed by -$1.24 B (-6672.33%)